Please login to the form below

Not currently logged in

Bayer's eye drug Eylea approved in Europe

Will compete with Novartis' Lucentis in wet AMD

 Bayer - research centre Berlin

The European Commission has approved Bayer's Eylea (aflibercept) to treat neovascular wet age-related macular degeneration (AMD), the leading cause of acquired blindness.

Bayer has blockbuster ambitions for the drug, whose sales are predicted to eventually exceed $1.1bn, and this new approval sets Eylea up to compete with Novartis' Lucentis (ranibizumab) in wet AMD in Europe.

One of Eylea's key selling points is likely to be its dosing. Bayer's drug is given every two months after three initial monthly injections, where-as Lucentis is given monthly until maximum visual acuity is achieved (is stable for three consecutive monthly assessments) and then resumed, on the same basis, when monitoring indicates loss of visual acuity due to wet AMD.

Bayer is also likely to compete on drug pricing, following a similar strategy in the US. Eylea was approved by the FDA last year, and was launched and marketed by Bayer's development partner Regeneron at a modest discount to Lucentis.

However, like Lucentis, Eylea could also face competition from Roche's cancer drug Avastin, which is much cheaper than both when used off-label to treat wet AMD.

The condition is the leading cause of blindness for people over the age of 65 in the US and Europe and sees new blood vessels grow beneath the retina and leak blood and fluid, creating blind spots and potentially loss of sight.

Dr Kemal Malik, Bayer's head of global development, said: “The approval of Eylea in Europe is great news for the increasing number of patients suffering from wet AMD, a sight threatening eye condition.

“Furthermore we are very pleased to announce already that we will launch Eylea in one of our biggest markets – Japan – very soon.”

Eylea, which is also known as VEGF trap eye, has completed phase III trials as a treatment for macular oedema following central retinal vein occlusion (CRVO) and is in late-stage trials for diabetic macular oedema (DME) and myopic choroidal neovascularisation (mCNV).

Bayer plans to submit drug, under its VEGF trap eye brand, for marketing authorisation in macular oedema following CRVO in Europe by the end of 2012.

28th November 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...